Ogeda Seeks Financing After Successful Phase II For Non-Hormonal Menopause Drug
Ogeda's non-hormonal menopause therapy, fezolinetant, has produced positive results in Phase II – an important step for the small Belgian biotech as it looks for partners or investment from further afield.
You may also be interested in...
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.